IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 7630)

VOLUNTARY ANNOUNCEMENT

IMPACT THERAPEUTICS ANNOUNCES IMP2794 AS A PRECLINICAL CANDIDATE (PCC), A HIGHLY KAT6A-SPECIFIC PROTAC FROM ITS PROPRIETARY TARGETED PROTEIN DEGRADATION PLATFORM

This announcement is made by IMPACT Therapeutics, Inc (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the Company's shareholders and potential investors about the latest business update of the Group.

The Company is pleased to announce that IMPACT Therapeutics has nominated IMP2794 as a pre-clinical candidate (PCC) of KAT6A specific PROTAC degrader. IMP2794 is the first PCC discovered by IMPACT Therapeutics using its proprietary Targeted Protein Degradation (TPD) Platform.

IMP2794 is a potent and selective KAT6A degrader, with over 1,000-fold selectivity against KAT6B. The compound displays potent in vitro cytotoxic activity against tumor cells and minimal hematopoietic toxicity. It demonstrates significant in vivo antitumor efficacy in both sensitive and insensitive breast cancer CDX models. Notably, IMP2794 achieves remarkably high oral bioavailability across multiple rodent and non-rodent species, indicating strong potential for optimal human systemic exposure.

KAT6A is a member of the MYST family of histone acetyltransferases (HATs) and catalyzes histone acetylation to promote an open chromatin state and activate gene transcription, which is highly expressed in various cancers, particularly in ER-positive (ER+) breast cancer. However, KAT6B, another homolog of KAT6A, shares structural and sequence similarities with KAT6A, making it challenging to achieve selective inhibition of the KAT6A through traditional modality of small molecular inhibitors. Inhibition of KAT6B simultaneously is associated with potential hematopoietic toxicities.

This nomination represents IMPACT Therapeutics' first PCC from its proprietary targeted protein degradation platform encompassing Proteolysis Targeting Chimeras (PROTACs), validating the platform's technical maturity and productivity. The Company has established this platform utilizing an E3 ligand library and a linker library for rapid PROTAC assembly, which is expected to confer good oral bioavailability. These tools enable selective and tunable degradation of previously "undruggable" targets, expanding therapeutic windows and reducing toxicity. Mechanistic complementarity with the Company's ADC platform supports a multi-dimensional approach to cancer target exploration.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to ultimately develop, manufacture and/or commercialize IMP2794. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of Directors
IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, August 12, 2026

As at the date of this announcement, the board of directors of the Company comprise (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive Directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive Directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive Directors.